down arrow

MoonLake Immunotherapeutics

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: KY61559X1045
USD
14.99
2.47 (19.77%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

13.3515.25

52 Week

5.9562.75
Valuation
Technical
Day's Volume

CASH

4.07 M

Shareholding (Mar 2025)

FII

12.23%

Held by 90 FIIs

DII

59.19%

Held by 33 DIIs

Promoter

2.60%

How big is MoonLake Immunotherapeutics?

22-Jun-2025

As of Jun 18, MoonLake Immunotherapeutics has a market capitalization of 2,760.75 million, categorizing it as a Small Cap company. As of Dec 24, Shareholder's Funds are 446.83 million and Total Assets are 477.93 million, with net sales of 0.00 million and a net profit of -147.83 million for the latest four quarters.

As of Jun 18, MoonLake Immunotherapeutics has a market capitalization of 2,760.75 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 24, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -147.83 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds at 446.83 million and Total Assets at 477.93 million.

Read More

What does MoonLake Immunotherapeutics do?

22-Jun-2025

MoonLake Immunotherapeutics is a small-cap biotechnology company focused on healthcare, currently reporting a net profit loss of $41 million and a market cap of $2.76 billion. It has no dividend yield and negative return on equity.

Overview:<BR>MoonLake Immunotherapeutics is a company in the Pharmaceuticals & Biotechnology industry, focused on healthcare, and operates within the small-cap market segment.<BR><BR>Financial Snapshot:<BR>- Most recent Net Profit: -41 Million (Quarterly Results - Mar 2025)<BR>- Market-cap: USD 2,760.75 Million (Small Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -1.00<BR>- Return on Equity: -36.27%<BR>- Price to Book: 6.77<BR><BR>Contact Details:<BR>- Address: C/O Cormorant Asset Management, Llp, 200 Clarendon Street Fl 52 BOSTON MA : 02116<BR>- Tel: 1 857 7020370

Read More

Is MoonLake Immunotherapeutics technically bullish or bearish?

07-Oct-2025

As of October 3, 2025, MoonLake Immunotherapeutics shows a mildly bearish trend with bearish MACD and KST indicators, despite a bullish RSI and mildly bullish daily moving averages, reflecting a significant decline of -85.43% over the past month compared to the S&P 500's 4.15%.

As of 3 October 2025, the technical trend for MoonLake Immunotherapeutics has changed from bullish to mildly bearish. The weekly MACD and KST indicators are both bearish, while the RSI shows a bullish signal. However, the Bollinger Bands and Dow Theory indicate a mildly bearish stance on the weekly timeframe. Daily moving averages are mildly bullish, providing some support. <BR><BR>In terms of performance, the stock has seen a significant decline with a 1-month return of -85.43% compared to the S&P 500's 4.15%, and a year-to-date return of -84.01% versus the S&P 500's 14.18%. Overall, the current technical stance is mildly bearish, reflecting weakness across multiple indicators despite some short-term bullish signals.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 3,926 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.99

stock-summary
Return on Equity

-50.64%

stock-summary
Price to Book

11.10

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-56 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-74.8%
0%
-74.8%
6 Months
-69.11%
0%
-69.11%
1 Year
-70.77%
0%
-70.77%
2 Years
-67.47%
0%
-67.47%
3 Years
49.2%
0%
49.2%
4 Years
52.08%
0%
52.08%
5 Years
42.81%
0%
42.81%

MoonLake Immunotherapeutics for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is MoonLake Immunotherapeutics technically bullish or bearish?

As of 3 October 2025, the technical trend for MoonLake Immunotherapeutics has changed from bullish to mildly bearish. The weekly MACD and KST indicators are both bearish, while the RSI shows a bullish signal. However, the Bollinger Bands and Dow Theory indicate a mildly bearish stance on the weekly timeframe. Daily moving averages are mildly bullish, providing some support. In terms of performance, the stock has seen a significant decline with a 1-month return of -85.43% compared to the S&P 500's 4.15%, and a year-to-date return of -84.01% versus the S&P 500's 14.18%. Overall, the current technical stance is mildly bearish, reflecting weakness across multiple indicators despite some short-term bullish signals....

Read More

Is MoonLake Immunotherapeutics technically bullish or bearish?

As of 3 October 2025, the technical trend for MoonLake Immunotherapeutics has changed from bullish to mildly bearish. The current technical stance is mildly bearish, driven by bearish MACD readings on both weekly and monthly timeframes, along with a bearish signal from the Bollinger Bands on the weekly chart. The KST and OBV indicators also reflect a mildly bearish sentiment on the weekly, while the daily moving averages show a mildly bullish signal. The RSI is bullish on the weekly but has no signal on the monthly, indicating mixed momentum. In terms of performance, the stock has significantly underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -84.43% versus the S&P 500's 14.18%....

Read More

Is MoonLake Immunotherapeutics technically bullish or bearish?

As of 19 September 2025, the technical trend for MoonLake Immunotherapeutics has changed from bullish to mildly bullish. The weekly MACD is bullish, and the monthly MACD is also bullish, supporting a positive outlook. The daily moving averages are bullish, while the weekly Bollinger Bands indicate a bullish stance and the monthly Bollinger Bands are mildly bullish. However, the KST shows a mixed signal with the weekly being bullish and the monthly mildly bearish. Dow Theory presents a mildly bearish view on the weekly timeframe but is mildly bullish on the monthly. The stock has a strong 3-year return of 653.15%, significantly outperforming the S&P 500's 70.89% over the same period. Overall, the current technical stance is mildly bullish, driven primarily by the bullish MACD and moving averages, despite some mixed signals from KST and Dow Theory....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-475.84%
EBIT to Interest (avg)
-75.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.00
Sales to Capital Employed (avg)
0
Tax Ratio
0.25%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
7.39
EV to EBIT
-15.25
EV to EBITDA
-15.41
EV to Capital Employed
1412.25
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-9260.06%
ROE (Latest)
-36.27%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bearish
OBV
No Trend
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 43 Schemes (25.98%)

Foreign Institutions

Held by 90 Foreign Institutions (12.23%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -126.21% vs -100.00% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-60.00",
          "val2": "-30.60",
          "chgp": "-96.08%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-56.10",
          "val2": "-24.80",
          "chgp": "-126.21%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -174.83% vs 31.63% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-141.70",
          "val2": "-54.10",
          "chgp": "-161.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-121.20",
          "val2": "-44.10",
          "chgp": "-174.83%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-60.00
-30.60
-96.08%
Interest
2.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-56.10
-24.80
-126.21%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -126.21% vs -100.00% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-141.70
-54.10
-161.92%
Interest
0.00
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-121.20
-44.10
-174.83%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -174.83% vs 31.63% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About MoonLake Immunotherapeutics stock-summary
stock-summary
MoonLake Immunotherapeutics
Pharmaceuticals & Biotechnology
Helix Acquisition Corp is a blank check company. The Company is incorporated for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company is primarily focused on the healthcare industry.
Company Coordinates stock-summary
Company Details
C/O Cormorant Asset Management, Llp, 200 Clarendon Street Fl 52 BOSTON MA : 02116
stock-summary
Tel: 1 857 7020370
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."